To address these changes, Sketchy did not just add a few videos; they re-engineered their entire curriculum, updated their interface, and refined their art style. What’s New in the Updated Sketchy Medical Videos?

Navigating a complex image can be tough when you are trying to review a single specific fact. Updated videos are accompanied by interactive, clickable "hotspots." You can hover over any part of the completed sketch to instantly see a pop-up explanation of what that symbol means, eliminating the need to scrub through a 20-minute video just to remember one drug interaction. What Content Got the Biggest Overhaul?

The website now supports Dark Mode , and a new Theater Mode ensures seamless progression between lessons. 4. Retired & Refreshed Content

Humans are designed to remember stories, not dry facts. Sketchy converts the mechanism of action of a drug into a cartoon character, making it much easier to recall that character—and the drug—six months later. 2. High-Yield Focus

[Your Name/Assistant]

: Allow for seamless review and navigation within the sketches.

Traditional video lectures are passive. DDx changes that by placing the student in the driver's seat of a differential diagnosis. The tool combines generative AI with expert-authored medical content, allowing students to engage in natural conversations with virtual patients. The results of early pilots have been striking. In a study with Charles Drew University, after using DDx, and 96% wanted to use it throughout their entire education . Faculty rated the educational value of the video cases at 4.8 out of 5, noting that students were not just memorizing but thinking through real-world problems.

: An "attending physician" provides instant feedback and hints on diagnostic reasoning, test ordering (like EKGs and labs), and differential building.

After watching a video, do UWorld questions on that topic to see how the mnemonic translates to a clinical scenario.

Medical pharmacology changes constantly. now explicitly exclude outdated medications (like older antiarrhythmics that are no longer first-line) and have integrated GLP-1 agonists (Ozempic/Wegovy) into the diabetes sketches. They have also added new sketches for Monoclonal Antibodies used in oncology, which were previously a weak spot in the catalog.